−0.6098USD
−8.40 MUSD
7.45 M
About Monopar Therapeutics Inc.
Sector
Industry
CEO
Chandler Drew Robinson
Website
Headquarters
Wilmette
Employees (FY)
10
Founded
2014
ISIN
US61023L1089
FIGI
BBG00J7K8D90
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MNPR is 0.6780 USD — it has increased by 3.51% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Monopar Therapeutics Inc. stocks are traded under the ticker MNPR.
Monopar Therapeutics Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
MNPR stock is 9.86% volatile and has beta coefficient of 2.49. Check out the list of the most volatile stocks — is Monopar Therapeutics Inc. there?
One year price forecast for Monopar Therapeutics Inc. has a max estimate of 6.0000 USD and a min estimate of 2.0000 USD.
MNPR earnings for the last quarter are −0.14 USD whereas the estimation was −0.15 USD which accounts for 8.70% surprise. Estimated earnings for the next quarter are −0.16 USD. See more details about Monopar Therapeutics Inc. earnings.
Yes, you can track Monopar Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
MNPR stock has fallen by 9.96% compared to the previous week, the month change is a 11.95% fall, over the last year Monopar Therapeutics Inc. has showed a 47.03% decrease.
MNPR net income for the last quarter is −1.81 M USD, while the quarter before that showed −1.95 M USD of net income which accounts for 7.16% change. Track more Monopar Therapeutics Inc. financial stats to get the full picture.
Today Monopar Therapeutics Inc. has the market capitalization of 11.43 M, it has decreased by 6.09% over the last week.
No, MNPR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MNPR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Monopar Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 10.00 employees. See our rating of the largest employees — is Monopar Therapeutics Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Monopar Therapeutics Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Monopar Therapeutics Inc. stock shows the sell signal. See more of Monopar Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Monopar Therapeutics Inc. future price: according to them, MNPR price has a max estimate of 6.00 USD and a min estimate of 2.00 USD. Read a more detailed Monopar Therapeutics Inc. forecast: see what analysts think of Monopar Therapeutics Inc. and suggest that you do with its stocks.